Almasry Pharmacy

Diacurimap 10 Mg 30 Tablets

Short Description:
Diacurimap 10 mg 30 tablets contains empagliflozin, an SGLT2 inhibitor used to lower blood sugar in adults with type 2 diabetes alongside diet and exercise. It also helps reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. For adult use only and must be taken under medical supervision.

EGP 204

In Stock

delivery-iconDelivery to governorates within 3-4 working days
refund-iconEasy returns within 14 days
Specifications
SKUISG002767
BrandدايكوريمابLink Icon
Categories
Medication & Treatments
Color
black
Concentrations
10 Mg
Shop by ConcernsCardiovascular Risk FactorsLink Icon, High Blood SugarLink Icon, Type 2 DiabetesLink Icon
Gender
Neutral
Shop By GoalsBlood ThinningLink Icon, Chest Pain ManagementLink Icon, Type 2 Diabetes ManagementLink Icon
Imported Or LocalLocal
Ingredient
Empagliflozin
UPC
6223003206352
Product Form
Tablets
Specialty
Clinically Tested
Prescription only
SGLT2 Inhibitor
Sub Categories
Insulin And Diabetic Medicines
Unit Count
30 Tablets
Warning
Avoid in severe kidney impairment or dialysis
Not for diabetic ketoacidosis
Not for type 1 diabetes
Not Recommended in Pregnancy or Breastfeeding
Use under medical supervision only
About the product

Diacurimap 10 Mg 30 Tablets

Description:

Diacurimap 10 mg 30 tablets is a prescription oral antidiabetic medicine containing empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It is used as part of a comprehensive diabetes care plan, along with diet and exercise, to help lower high blood sugar levels in adults with type 2 diabetes mellitus. Diacurimap can be used alone or in combination with other antidiabetic medicines and also helps reduce the risk of cardiovascular death in adults with type 2 diabetes who have established cardiovascular disease. This medicine is not indicated for type 1 diabetes or diabetic ketoacidosis and is not recommended for children and adolescents under 18 years.


Indications:

  • Management of blood glucose levels in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
  • Can be used as monotherapy or in combination with other antidiabetic agents (such as metformin, insulin, or others) when additional glycemic control is needed.
  • Reduction of the risk of cardiovascular death in adults with type 2 diabetes and known cardiovascular disease.
  • Helps improve glycemic control by increasing urinary glucose excretion, thereby lowering fasting and postprandial blood sugar levels.

Active Ingredients / Key Components:

  • Empagliflozin – 10 mg per film-coated tablet.
  • Other excipients: Full list of inactive ingredients (tablet core and film coating) is not available in the provided information. Please refer to the official package insert for complete excipient details.

Dosage & Administration / How to Use:

  • Recommended dose for adults: Typically 10 mg empagliflozin once daily, taken orally. The dose may be adjusted by the prescribing physician based on individual response and tolerability, according to approved guidelines.
  • Administration: Swallow the tablet whole with water. It can be taken with or without food, at the same time each day for best adherence.
  • Do not crush, break, or chew the tablets.
  • If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose to make up for a missed one.
  • Use only under medical supervision. Your doctor may adjust the dose or combine it with other antidiabetic medicines based on your blood sugar levels, kidney function, and overall health.
  • Regular monitoring of blood glucose, kidney function, and cardiovascular status is recommended during treatment.

Clinical Benefits:

  • Helps significantly lower elevated blood sugar levels in adults with type 2 diabetes when used with diet and exercise.
  • Reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
  • Promotes additional glucose excretion through the urine by inhibiting SGLT2 in the kidneys, leading to improved glycemic control.
  • May contribute to modest weight reduction and a decrease in blood pressure in some patients, as a result of its mechanism of action (increased urinary glucose and sodium loss).

Warnings & Contraindications:

  • Do not use Diacurimap (empagliflozin) if you have type 1 diabetes, as it is not effective and may increase the risk of diabetic ketoacidosis.
  • Contraindicated in patients with diabetic ketoacidosis (increased ketones in blood or urine), regardless of diabetes type.
  • Do not take this medicine if you have severe kidney problems or are on dialysis. Empagliflozin efficacy and safety are reduced in severe renal impairment.
  • Not recommended for children and adolescents under 18 years of age due to insufficient safety and efficacy data.
  • Should not be used during pregnancy or breast-feeding. If you become pregnant or plan to breast-feed, inform your doctor immediately to switch to a safer alternative.
  • Use with caution in patients with a history of recurrent urinary tract infections, genital infections, low blood pressure, or dehydration, as empagliflozin can increase the risk of these conditions.
  • May increase the risk of volume depletion, especially in elderly patients, those on diuretics, or those with low blood pressure. Monitor for dizziness, fainting, or weakness.
  • Inform your doctor if you have liver disease, moderate kidney impairment, cardiovascular disease, or are taking diuretics, blood pressure medications, or other antidiabetic drugs.
  • Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as kidney disease, liver disease, cardiovascular disease, or a history of ketoacidosis.
  • Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision. It must be used strictly according to your doctor’s prescription.
  • Keep out of reach of children.

Side Effects:
  • Common side effects may include urinary tract infections, genital fungal infections (such as yeast infections), increased urination, thirst, and mild dehydration.
  • Other possible side effects: dizziness or low blood pressure (especially when standing), increased cholesterol levels, or mild nausea.
  • Serious but less common side effects may include ketoacidosis (with symptoms such as nausea, vomiting, abdominal pain, difficulty breathing, confusion, unusual fatigue), severe urinary tract infections, or severe dehydration. Seek immediate medical attention if these occur.
  • Allergic reactions are rare but may present with rash, itching, swelling (especially of the face, tongue, or throat), severe dizziness, or difficulty breathing. Stop the medicine and seek urgent medical help if signs of allergy appear.
  • This is not a complete list of side effects. Always read the patient leaflet and consult your doctor or pharmacist if you notice any unusual symptoms.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.


Specifications:
  • Form: Film-coated tablets.
  • Strength: 10 mg empagliflozin per tablet.
  • Pack size: 30 tablets per pack.
  • Intended use: Prescription antidiabetic medicine for adults with type 2 diabetes.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.

Product Reviews

Overall Rating
0

Based on 0 reviews

Warning iconYou can add a rating once you purchase the product through the My Orders page

Customer Reviews
No reviews yet
TelegramWhatsApp